TLX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

7.110

Open

7.020

VWAP

7.04

Vol

192.75K

Mkt Cap

2.36B

Low

6.940

Amount

1.36M

EV/EBITDA(TTM)

102.63

Total Shares

334.72M

EV

4.93B

EV/OCF(TTM)

242.31

P/S(TTM)

3.63

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

Show More

Events Timeline

(ET)

2026-01-20

07:10:00

Telix Medicine Reports Significant Revenue Growth in Q4 2025

2026-01-16 (ET)

2026-01-16

14:30:00

Telix Pharmaceuticals Launches Prostate Cancer Clinical Trial in the U.S.

2025-12-10 (ET)

2025-12-10

07:10:00

Telix Pharmaceuticals Announces Strategic Clinical Collaboration with Varian

2025-10-23 (ET)

2025-10-23

07:15:38

Telix Pharmaceuticals 'applauds' revised SNMII guidelines for TLX250-CDx

2025-10-22 (ET)

2025-10-22

16:04:37

Telix Pharmaceuticals Administers First Dose to Patient in TLX090 Trial

2025-10-14 (ET)

2025-10-14

05:36:13

Telix Pharmaceuticals increases FY25 revenue forecast to $800M-$820M, up from $770M-$800M

2025-10-14

05:33:47

Telix Pharmaceuticals announces Q3 revenue of $206M, up from $135M last year.

News

Newsfilter

02-03Newsfilter

Telix Pharmaceuticals to Release Full Year Results for 2025

Benzinga

Telix Pharmaceuticals Reports FY 2025 Revenue of $804 Million Amid 56.91% Stock Decline

Benzinga

Netflix Reports Q4 Results, Q1 Guidance Misses Estimates

NASDAQ.COM

01-20NASDAQ.COM

Telix Pharmaceuticals Reports Q4 Revenue Increase to $208 Million

Yahoo Finance

01-16Yahoo Finance

Health Care Stocks Decline as NYSE Health Care Index Eases 0.5%

Globenewswire

01-16Globenewswire

Telix Doses First Patient in BiPASS™ Trial for Prostate Cancer Imaging

Valuation Metrics

The current forward P/E ratio for Telix Pharmaceuticals Ltd (TLX.O) is 207.95, compared to its 5-year average forward P/E of 110.33. For a more detailed relative valuation and DCF analysis to assess Telix Pharmaceuticals Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

110.33

Current PE

207.95

Overvalued PE

185.63

Undervalued PE

35.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

53.59

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

62.95

Undervalued EV/EBITDA

44.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

5.56

Current PS

0.00

Overvalued PS

7.44

Undervalued PS

3.67

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks with highest short ratio

Intellectia · 11 candidates

Market Cap: >= 1000.00MRelative Vol: >= 1.20Short Ratio: MoreThan30PctWeekly Average Turnover: >= 1,000,000Month Price Change Pct: <= $-2.00

Ticker

Name

Market Cap$

Expedia Group Inc

33.27B

Willis Towers Watson PLC

30.55B

AXIS Capital Holdings Ltd

7.96B

Birkenstock Holding PLC

7.24B

MakeMyTrip Ltd

6.22B

Pampa Energia SA

4.48B

Whales Holding TLX

Challenger Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Telix Pharmaceuticals Ltd (TLX) stock price today?

The current price of TLX is 7.08 USD — it has decreased -0.28 % in the last trading day.

What is Telix Pharmaceuticals Ltd (TLX)'s business?

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

What is the price predicton of TLX Stock?

Wall Street analysts forecast TLX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Telix Pharmaceuticals Ltd (TLX)'s revenue for the last quarter?

Telix Pharmaceuticals Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Telix Pharmaceuticals Ltd (TLX)'s earnings per share (EPS) for the last quarter?

Telix Pharmaceuticals Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

How many employees does Telix Pharmaceuticals Ltd (TLX). have?

Telix Pharmaceuticals Ltd (TLX) has 0 emplpoyees as of February 10 2026.

What is Telix Pharmaceuticals Ltd (TLX) market cap?

Today TLX has the market capitalization of 2.36B USD.